Pherrinx

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group headquartered in Saint-Prex, Switzerland. Founded in 1950, the company is a global leader in reproductive medicine and maternal health, while also maintaining a strong presence in urology, gastroenterology, and endocrinology. Ferring is at the forefront of innovation in microbiome-based therapeutics and uro-oncology gene therapy, with key products including Rebyota for recurrent C. difficile infection and Adstiladrin for non-muscle invasive bladder cancer. The company operates in over 50 countries and distributes its products to more than 100 countries worldwide.